top of page

Direct to Bladder Therapies

About UroPharma

  • UroPharma has patented and developed the world’s first licensed ‘direct to bladder’ drug delivery system, that will be in the market by early 2023.

  • This overcomes clinical limitations and significant harms caused by the oral delivery of drugs intended for bladder therapy.

  • The design incorporates safety features intended to reduce costs associated with treating catheter acquired urinary tract infections caused by antibiotic resistance.

  • Urinary tract infections represent a substantial cost burden to the healthcare system and catheters are the biggest contributors to this global problem.

  • Urinary Tract Infections, Overactive Bladder, incontinence, Multiple Sclerosis and Spinal Cord Injury are a substantial reducer of quality of life with millions of people.

We’ll be very interested in your feedback and questions

Recent Posts

See All

The urobiome

Following on from revelations that we have a complex symbiotic relationship with our #gut microbiome, the discovery that we also have a #urobiome has attracted much attention. There’s no going back to

"We know almost nothing about managing UTI"

“We know almost nothing about managing UTI.” This assertion went unchallenged at the British Society of #Antimicrobial Chemotherapy multidisciplinary conference of experts last year. Increasingly, we

GAG-layer supplements

From Prof. Scott Glickman: A GAG (#glycosaminoglycan) layer within the #bladder, as a nanometres-thick coating, surely would be less than 2ml. Why do companies sell costly GAG-layer supplements as 50m

bottom of page